New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 12, 2014
08:09 EDTACT, VRXActavis announces patent challenge settlement for Acanya
Actavis (ACT) announced that it has entered into an agreement with Valeant (VRX) to settle all outstanding patent litigation related to Actavis' generic version of Acanya Gel, 1.2%/2.5%. Acanya Gel is a lincosamide antibiotic and benzoyl peroxide indicated for the topical treatment of acne vulgaris. Under the terms of the agreement, Valeant will grant Actavis a license to market its generic Acanya Gel beginning in July 1, 2018 or earlier under certain circumstances. Other details of the settlement were not disclosed. For the 12 months ending February 28, Acanya® had total U.S. sales of approximately $121M, according to IMS Health data.
News For ACT;VRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
October 20, 2014
07:06 EDTVRXValeant raises FY15 outlook cash EPS $10.00 from $9.90
Subscribe for More Information
07:05 EDTVRXValeant raises Q4 cash EPS $2.45-$2.55 from $2.35-$2.45
Subscribe for More Information
07:03 EDTVRXValeant reports Q3 cash EPS $2.11, Q3 GAAP EPS 81c
Reports Q3 revenue revenue $2.1B; Reports Q3 total same store sales organic growth 19%. Bausch + Lomb organic growth was 12%. Q3 GAAP Operating Cash Flow $619 million, an increase of 207%; Adjusted Operating Cash Flow $771 million, an increase of 89%
06:28 EDTACTAllergan price target raised to $210 from $190 at Citigroup
Subscribe for More Information
October 17, 2014
09:47 EDTVRX, ACTValeant will not raise Allergan bid ahead of record date, CNBC reports
Valeant (VRX) will not raise its hostile takeover bid for Allergan (AGN) ahead of the record date for the vote, CNBC's David Faber reports. Allergan (AGN) is not currently in takeover talks with Actavis (ACT), Faber added.
09:45 EDTACTAllergan not in deal talks with Actavis, CNBC reports
09:43 EDTVRXValeant not going to raise Allergan bid ahead of meeting, CNBC reports
Subscribe for More Information
October 16, 2014
17:27 EDTACTNoven files patent infringement suit against Actavis
Subscribe for More Information
15:10 EDTACTAmerican College of Gastroenterology to hold annual meeting
ACG Annual Scientific Meeting 2014 to be held in Philadlephia, PA on October 17-22.
12:42 EDTVRXAckman believes Allergan, Valeant merger likely, CNBC reports
Subscribe for More Information
12:38 EDTVRXAckman says Allergan CEO manipulated Valeant shares, CNBC reports
Subscribe for More Information
08:08 EDTACTActavis confirms generic Quillivant XR patent challenge
Subscribe for More Information
08:02 EDTACTIronwood announces initiation of Phase II linaclotide trial
Ironwood Pharmaceuticals (IRWD) announced the initiation of a Phase II clinical trial evaluating linaclotide for the treatment of adults suffering from opioid-induced constipation. Data are expected in the second half of 2015. The clinical trial is being conducted jointly by Ironwood and Actavis plc (ACT), Ironwood’s co-development and co-promotion partner for linaclotide in the United States. Linaclotide is a guanylate cyclase-C agonist approved by the FDA for the treatment of adults with irritable bowel syndrome with constipation or chronic idiopathic constipation. Linaclotide is not currently approved for the treatment of OIC. The randomized, double-blind, placebo-controlled, multi-site Phase II clinical trial is expected to enroll approximately 240 adult patients with chronic, non-cancer pain who have been receiving a stable dose of an opioid analgesic and suffer from constipation, defined as fewer than three spontaneous bowel movements per week. Patients will be randomized to receive 145 mcg of linaclotide, 290 mcg of linaclotide, or placebo for eight weeks. The primary endpoint of the trial is an increase in SBM frequency. Additionally, a number of secondary endpoints and exploratory analyses intended to inform future development plans are included in the study design.
October 15, 2014
13:07 EDTVRXAllergan seeing arb-related selling pressure, says BMO Capital
Subscribe for More Information
October 14, 2014
07:46 EDTACTActavis should be able to mitigate Irish tax downside, says Leerink
Subscribe for More Information
06:03 EDTACTMarket overreacted to new Irish tax rules, says BMO Capital
BMO Capital believes the market may have overreacted yesterday to the report that Ireland is eliminating the "Double Irish" tax loophole. The firm says Allergan (AGN) confirmed that it incorporated potential changes to Irish tax law in its recently raised earnings guidance while Mallinckrodt (MNK) said it does expect the new tax structure to have an immediate impact. BMO views yesterday's pullback in shares of Allergan, Mallinckrodt and Actavis (ACT) as an overreaction.
October 13, 2014
15:12 EDTACTActavis may see modest negative impact from Irish tax change, says BMO Capital
Subscribe for More Information
October 10, 2014
10:20 EDTACTFidelity supports potential merger between Actavis and Allergan, Reuters reports
Subscribe for More Information
07:37 EDTACT, VRXActavis more likely partner than Valeant if Allergan merges, says UBS
Subscribe for More Information
07:16 EDTVRXAmerican Society of Plastic Surgeons to hold annual meeting
Annual Meeting of ASPS is being held in Chicago on October 10-14.
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use